We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Polarean Imaging Plc | LSE:POLX | London | Ordinary Share | GB00BF3DT583 | ORD GBP0.00037 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.05 | -1.28% | 3.85 | 3.70 | 4.00 | 3.90 | 3.85 | 3.90 | 159,492 | 08:33:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Surgical,med Instr,apparatus | 1.03M | -13.91M | -0.0644 | -0.60 | 8.31M |
TIDMPOLX
RNS Number : 6602M
Polarean Imaging PLC
25 January 2021
Polarean Imaging Plc
("Polarean" or the "Company")
Change of Nominated Adviser
Polarean Imaging plc (AIM: POLX), the medical--imaging technology company, with a proprietary drug--device combination product using hyperpolarised xenon-129 gas to enhance magnetic resonance imaging (MRI) in pulmonary medicine, announces the appointment of Stifel Nicolaus Europe Limited as Nominated Advisor ("NOMAD") with immediate effect.
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com Richard Hullihen, Chief Executive Via Walbrook PR Officer Jonathan Allis, Chairman Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker) +44 (0)20 7710 7600 Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare Investment Banking) Nick Adams / Fred Walsh (Corporate Broking) Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / +44 (0)7876 741 001
About Polarean ( www.polarean.com )
The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution medical imaging market.
The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.
The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate and less harmful to the patient than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
APPGZGZMVZMGMZM
(END) Dow Jones Newswires
January 25, 2021 02:00 ET (07:00 GMT)
1 Year Polarean Imaging Chart |
1 Month Polarean Imaging Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions